Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul D Morrison

Showing results (61-70 of 73) with videos related to

Pageof 8
Sort By:
Journal of Psychopharmacology (Oxford, England)|October 15, 2015
Genetic moderation of the effects of cannabis: catechol-O-methyltransferase (COMT) affects the impact of Δ9-tetrahydrocannabinol (THC) on working memory performance but not on the occurrence of psychotic experiencesElizabeth M Tunbridge, Graham Dunn, Robin M Murray, et al.
Inflammatory Bowel Diseases|November 9, 2016
Fecal Microbiota and Metabolome in a Mouse Model of Spontaneous Chronic Colitis: Relevance to Human Inflammatory Bowel DiseaseAinsley M Robinson, Shakuntla V Gondalia, Avinash V Karpe, et al.
Microorganisms|October 9, 2019
Influence of Human Activities on Broad-Scale Estuarine-Marine Habitats Using Omics-Based Approaches Applied to Marine SedimentsRohan M Shah, Joseph Crosswell, Suzanne S Metcalfe, et al.
Analytical Chemistry|May 6, 2010
Characterization of tetra-aryl benzene isomers by using preparative gas chromatography with mass spectrometry, nuclear magnetic resonance spectroscopy, and X-ray crystallographic methodsChristian P G Rühle, Julie Niere, Paul D Morrison, et al.
Journal of Psychopharmacology (Oxford, England)|September 21, 2010
Does intravenous Δ9-tetrahydrocannabinol increase dopamine release? A SPET studyEmma Barkus, Paul D Morrison, D Vuletic, et al.
Clinical Pharmacokinetics|October 16, 2014
Population pharmacokinetic model of THC integrates oral, intravenous, and pulmonary dosing and characterizes short- and long-term pharmacokineticsJules A A C Heuberger, Zheng Guan, Olubukayo-Opeyemi Oyetayo, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|December 15, 2010
Disruption of frontal θ coherence by Δ9-tetrahydrocannabinol is associated with positive psychotic symptomsPaul D Morrison, Judith Nottage, James M Stone, et al.
Journal of Psychopharmacology (Oxford, England)|October 9, 2012
Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairmentAmir Englund, Paul D Morrison, Judith Nottage, et al.
Psychopharmacology|March 23, 2018
Group II metabotropic glutamate receptor agonist prodrugs LY2979165 and LY2140023 attenuate the functional imaging response to ketamine in healthy subjectsMitul A Mehta, Anne Schmechtig, Vasileia Kotoula, et al.
International Journal for Parasitology. Drugs and Drug Resistance|September 19, 2016
Metabolic profiling and in vitro assessment of anthelmintic fractions of Picria fel-terrae LourRasika Kumarasingha, Avinash V Karpe, Sarah Preston, et al.
Pageof 8

Showing results (61-70 of 73) with videos related to

Sort By:
Pageof 8
Journal of Psychopharmacology (Oxford, England)|October 15, 2015
Genetic moderation of the effects of cannabis: catechol-O-methyltransferase (COMT) affects the impact of Δ9-tetrahydrocannabinol (THC) on working memory performance but not on the occurrence of psychotic experiencesElizabeth M Tunbridge, Graham Dunn, Robin M Murray, et al.
Inflammatory Bowel Diseases|November 9, 2016
Fecal Microbiota and Metabolome in a Mouse Model of Spontaneous Chronic Colitis: Relevance to Human Inflammatory Bowel DiseaseAinsley M Robinson, Shakuntla V Gondalia, Avinash V Karpe, et al.
Microorganisms|October 9, 2019
Influence of Human Activities on Broad-Scale Estuarine-Marine Habitats Using Omics-Based Approaches Applied to Marine SedimentsRohan M Shah, Joseph Crosswell, Suzanne S Metcalfe, et al.
Analytical Chemistry|May 6, 2010
Characterization of tetra-aryl benzene isomers by using preparative gas chromatography with mass spectrometry, nuclear magnetic resonance spectroscopy, and X-ray crystallographic methodsChristian P G Rühle, Julie Niere, Paul D Morrison, et al.
Journal of Psychopharmacology (Oxford, England)|September 21, 2010
Does intravenous Δ9-tetrahydrocannabinol increase dopamine release? A SPET studyEmma Barkus, Paul D Morrison, D Vuletic, et al.
Clinical Pharmacokinetics|October 16, 2014
Population pharmacokinetic model of THC integrates oral, intravenous, and pulmonary dosing and characterizes short- and long-term pharmacokineticsJules A A C Heuberger, Zheng Guan, Olubukayo-Opeyemi Oyetayo, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|December 15, 2010
Disruption of frontal θ coherence by Δ9-tetrahydrocannabinol is associated with positive psychotic symptomsPaul D Morrison, Judith Nottage, James M Stone, et al.
Journal of Psychopharmacology (Oxford, England)|October 9, 2012
Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairmentAmir Englund, Paul D Morrison, Judith Nottage, et al.
Psychopharmacology|March 23, 2018
Group II metabotropic glutamate receptor agonist prodrugs LY2979165 and LY2140023 attenuate the functional imaging response to ketamine in healthy subjectsMitul A Mehta, Anne Schmechtig, Vasileia Kotoula, et al.
International Journal for Parasitology. Drugs and Drug Resistance|September 19, 2016
Metabolic profiling and in vitro assessment of anthelmintic fractions of Picria fel-terrae LourRasika Kumarasingha, Avinash V Karpe, Sarah Preston, et al.
Pageof 8